RxDoctor Payments Data

Philip Atigre, MD

Internal Medicine · Tampa, FLNPI 1871550483

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 14 payments — averaging $129.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alpha Cognition USA, Inc.$900
  • Inari Medical, Inc.$178
  • Sunovion Pharmaceuticals Inc.$135
  • Cook Medical LLC$135
  • Bayer$125
  • UCB, Inc.$118
  • plus $226 from 6 others

What the payments were for

  • Speaking & faculty fees$90050%
  • Food & beverage$91750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alpha Cognition USA, Inc.1$900
Inari Medical, Inc.1$178
Sunovion Pharmaceuticals Inc.2$135
Cook Medical LLC1$135
Bayer1$125
UCB, Inc.1$118
La Jolla Pharmaceutical Company1$115
Amgen2$35
Teva Pharmaceuticals USA, Inc.1$27
Cipher Pharmaceuticals US LLC1$21
Abbott1$17
Medtronic1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,817 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$761,728
Medicare patients
840
Services billed
6,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban938$358,012
OzempicSemaglutide80$103,487
XifaxanRifaximin72$99,108
OtezlaApremilast38$61,805
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$54,180
Glatiramer Acetate58$49,739
NuedextaDextromethorphan Hbr/Quinidine65$47,627
MounjaroTirzepatide40$45,222
Invega SustennaPaliperidone Palmitate14$44,969
JanuviaSitagliptin Phosphate90$44,268
TrulicityDulaglutide37$40,550
Dimethyl Fumarate16$38,201
EntrestoSacubitril/Valsartan49$34,920
SantylCollagenase Clostridium Hist.16$33,469
XareltoRivaroxaban33$27,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$35$61,80538 claims
Sunovion Pharmaceuticals Inc.Aptiom$135$14,90324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →